Rob Trangucci, Yang Chen, and Jon Zelner write: In order to meet regulatory approval, pharmaceutical companies often must demonstrate that new vaccines reduce the total risk of a post-infection outcome like transmission, symptomatic disease, severe illness, or death in randomized, … Continue reading …